Genome-wide association studies have identified a SNP, rs2294008, on 8q24.3 within the prostate stem cell antigen (PSCA) gene, as a risk factor for bladder cancer. To fine-map this region, we imputed 642 SNPs within 100 Kb of rs2294008 in addition to 33 markers genotyped in one of the reported genome-wide association study in 8,652 subjects. A multivariable logistic regression model adjusted for rs2294008 revealed a unique signal, rs2978974 (r 2 = 0.02, D′ = 0.19 with rs2294008). In the combined analysis of 5,393 cases and 7,324 controls, we detected a per-allele odds ratio (OR) = 1.11 [95% confidence interval (CI) = 1.06-1.17, P = 5.8 × 10 ] for rs2294008 and OR = 1.07 (95% CI = 1.02-1.13, P = 9.7 × 10 −3 ) for rs2978974. The effect was stronger in carriers of both risk variants (OR = 1.24, 95% CI = 1.08-1.41, P = 1.8 × 10 −3
) and there was a significant multiplicative interaction (P = 0.035) between these two SNPs, which requires replication in future studies. The T risk allele of rs2294008 was associated with increased PSCA mRNA expression in two sets of bladder tumor samples (n = 36, P = 0.0007 and n = 34, P = 0.0054) and in normal bladder samples (n = 35, P = 0.0155), but rs2978974 was not associated with PSCA expression. SNP rs2978974 is located 10 Kb upstream of rs2294008, within an alternative untranslated first exon of PSCA. The non-risk allele G of rs2978974 showed strong interaction with nuclear proteins from five cell lines tested, implying a regulatory function. In conclusion, a joint effect of two PSCA SNPs, rs2294008 and rs2978974, suggests that both variants may be important for bladder cancer susceptibility, possibly through different mechanisms that influence the control of mRNA expression and interaction with regulatory factors. U rinary bladder cancer ranks as the ninth most common malignancy worldwide (1) and the sixth in the United States, with 73,510 new cases and 14,880 deaths expected in the United States in 2012 (2) . Because of a 70% 10-y survival rate and 50-70% recurrence rate (3), patients require life-long surveillance and treatment, making bladder cancer one of the most expensive cancers to live with and a major economic burden on the health care system (4, 5) . Cigarette smoking and occupational exposures to aromatic amines are established risk factors for bladder cancer (6) .
Genetic factors are estimated to explain 7-31% of bladder cancer susceptibility (7, 8) . Traditional candidate gene association studies focused on genes involved in detoxification of environmental carcinogens and DNA repair pathways (9-12). Recently, genome-wide association studies (GWAS) have advanced our knowledge of the genetic architecture of bladder cancer by discovering a number of new bladder cancer-associated loci (13) (14) (15) (16) (17) .
One of these variants to achieve genome-wide significance with bladder cancer was SNP rs2294008 (C/T) within the prostate stem cell antigen (PSCA) gene on 8q24.3 (14, 15) . PSCA is a glycosylphosphatidylinositol-anchored cell membrane glycoprotein initially identified as a prostate-specific cell-surface antigen (18) , but later found to be expressed in many human tissues. Humanized monoclonal anti-PSCA antibodies are currently under evaluation in clinical trials for the treatment of pancreatic and prostate cancers (19, 20) . Although many studies have supported the important role of PSCA in carcinogenesis, little is known about the function of PSCA in normal and tumor tissues.
In this study, we aimed to comprehensively explore the genetic landscape of the PSCA region to map genetic variants contributing to bladder cancer susceptibility, as well as to investigate the molecular phenotype of these variants and their role in cancer biology.
Results
Fine-Mapping and Genetic Association of the PSCA Region. PSCA is located in 8q24.3 locus, 12.5 Mb telomeric from the region associated with multiple cancers (21) . Based on the combined reference panel of the 1000 Genomes Project and HapMap 3 CEU (Utah residents with Northern and Western European ancestry) data, we expanded the SNP coverage of the 200 Kb PSCA region (chr8:
to 33 SNPs in the PSCA region genotyped in our stage 1 GWAS (14), we imputed 642 additional markers in the same 8,652 subjects. All markers passed the Hardy-Weinberg equilibrium test with a P value > 0.01 (Table S1 ). Of 675 markers in this region, 446 highquality markers were used for further association analysis, including 413 SNPs with IMPUTE2-info score ≥ 0.9 and 33 SNPs already genotyped in the GWAS. Sequencing of all the PSCA exons in 45 bladder tumor samples did not find any coding variants not already included in our analyses.
The strongest signal was for rs2976393 [odds ratio (OR) = 1.11, 95% confidence interval (CI) = 1.04-1.18, P = 1.62 × 10 ) (Fig. 1A) . Among the 21 SNPs with a P value lower than that of rs2294008, 17 variants showed similar effect size and were in moderate-to-high linkage disequilibrium (LD) with rs2294008 (r 2 = 0.53-0.99) (Dataset S1). To test for the presence of other disease-associated SNPs in this region, we adjusted for the effect of rs2294008 along with age, sex, study regions, and smoking habit, and found the strongest signal for an additional variant, already genotyped in the GWAS, rs2978974 (OR = 1.11, 95% CI = 1.04-1.19, P = 1.80 × 10 −3 ) ( Fig. 1B and Dataset S1). Among 446 markers examined in this study, 46 SNPs are in strong LD (r 2 > 0.8) with rs2294008, but rs2978974 is a unique variant that is in low LD with rs2294008 (D′ = 0.19, r 2 = 0.02) and not well tagged by other SNPs (r 2 max = 0.19) (Fig. S1 and Dataset S1). Additionally, rs2294008 and rs2978974 were genotyped in three independent studies, New England Bladder Cancer Study from New Hampshire (NEBCS-NH, a component of NEBCS not used in stage 1 GWAS), and Texas Bladder Cancer Study discovery set and validation set (TXBCS1 and TXBCS2, respectively). In the combined analysis of all eight studies that included 5,393 cases and 7,324 controls, rs2294008 and rs2978974 were associated with bladder cancer with a per-allele OR = 1.11 (95% CI = 1.06-1.17, P = 5.79 × 10 ) and OR = 1.07 (95% CI = 1.02-1.13, P = 9.66 × 10 −3 ), respectively ( Table 1) . Because rs2294008 and rs2978974 are in low LD but each showed evidence for association, we assessed the joint effect of these variants on bladder cancer risk ( Table 2) . Within the nine possible combinations of SNP genotypes, individuals carrying risk alleles contributed by both SNPs were at increased risk for bladder cancer, with individuals homozygous for risk alleles of both SNPs being at the highest risk (OR = 1.44, 95% CI = 1.08-1.94, P = 1.48 × 10 −2 ) ( Table 2) . In a dominant model for the two SNPs, individuals carrying variants of both SNPs had increased risk of bladder cancer (OR = 1.24, 95% CI = 1.08-1.41, P = 1.76 × 10 −3 ) ( Table 2 ). There were nominally significant interactions between rs2294008 and rs2978974: multiplicative, P value of log-likelihood ratio test = 0.035 (Table 2 ) and additive, P value for relative excess risk for interaction = 0.039 (Table S2) , also detected by a recently developed statistical method (22) (Table S2 ). The association results did not significantly differ by sex or tumor grade (Tables  S3-S5 ). We observed an interaction between the two-SNP jointeffect model with smoking status (P = 0.027) (Table S5) , with stronger bladder cancer risk among ever (vs. never) smokers carrying risk variants of both SNPs; however, this requires further confirmation studies.
PSCA mRNA Expression Analysis. RNA-sequencing in normal and tumor bladder tissue samples detected 11 PSCA isoforms, but most of them were expressed at low levels ( Fig. 2 and Table S6 ). PSCA was mainly found as a transcript that includes exons 1, 2, and 3 (PSCA-123, RefSeq NM_005672), with rs2294008 located within the first exon or 5′UTR of this transcript (Fig. 2) . The other bladder cancer-associated SNP, rs2978974, is located 10 Kb upstream of rs2294008 within an alternative untranslated first exon (exon 1a) spliced to exon 2, creating an isoform PSCA-1a2 [GenBank NR_033343.1 (23)] (Fig. 2) . This isoform is predicted to create a different ORF starting from exon 3 and generate a protein of 189 amino acids (Fig. S2) , without similarity to PSCA or any other known protein.
Microarray expression analysis in 37 bladder tumors showed significant association for the risk T allele of rs2294008 with increased PSCA expression (p trend = 0.0007) but there was no association for rs2978974 (p trend = 0.1495) (Fig. 3A) . We performed validation analysis with quantitative RT-PCR in 35 independent tumor bladder tissue samples using two custom-designed assays to detect the full-length PSCA transcript (PSCA-123) and a form with the alternative exon 1a (PSCA-1a2). PSCA-123 mRNA expression was strongly increased in individuals with risk T allele of rs2294008 (p trend = 0.0054) but not of rs2978974 (p trend = 0.9486) (Fig. 3B) . A similar pattern of expression was observed in 35 normal bladder tissue samples (p trend = 0.0155 for rs2294008 and p trend = 0.7297 for rs2978974) (Fig. 3C) . The genotype combination was not associated with PSCA expression (Fig. 3) . Expression of the alternative form PSCA-1a2 was significantly lower than of PSCA-123, and it was associated with rs2294008 only in tumor samples (Fig.  S3 ). There was significantly higher PSCA mRNA expression in tumors vs. normal bladder samples, with 7.3-fold (P = 0.0046) for the PSCA-123 but not for the PSCA-1a2 form (Fig. 4) . Analysis of 27 paired normal-tumor bladder tissue samples showed that the PSCA-123 expression was mainly affected by rs2294008 genotype but not the sample (normal-tumor) status (Fig. S4 ).
DNA-Protein Interaction. Although rs2978974 showed no association with PSCA mRNA expression, we hypothesized that it could have a regulatory effect because of its location within the first alternative untranslated exon. To further investigate the functional effect of this variant, we performed EMSA with allele-specific probes for rs2978974, using nuclear extracts from HeLa (cervix), LNCaP (prostate), LNCaP treated with dihydrotestosterone (DHT; a potent analog of testosterone), HTB-5 (bladder), and J82 (bladder) cancer cell lines. In all cell lines tested, there was a strong interaction with the probe for the non-risk G allele of rs2978974 (Fig. 5, lane 9) , but not for the risk allele A (Fig. 5, lane  2 ). There were two distinct bands in LNCaP cells but only one band appeared in the other cell lines, suggesting a tissue-specific pattern for this DNA-protein interaction. It was also evident that the binding with the protein extract from DHT-treated LNCaP cells was much stronger than with protein extracts from all other cells, suggesting a specific role of testosterone in this regulation. Competition assays with excess of unlabeled rs2978974 G probe confirmed that both bands were specific (Fig. 5, lanes 10 and 11) because the intensities of these bands were decreased. However, the excess of unlabeled rs2978974 A probe did not cause the same effect (Fig. 5, lanes 12 and 13) , confirming that the binding was specific for the G probe.
Two bioinformatic tools, AliBaba2 (24) and TFSearch (25), predicted interaction of the probe with the non-risk G allele of rs2978974 with proteins from the ETS family of transcription factors, specifically, with ELK1 (26), but no binding was predicted for the risk A allele (Fig. S5) . After adding anti-ELK1 antibodies into binding reactions, we observed a moderate decrease of binding in the LNCaP cells, but there was no effect of ELK1 antibodies in HeLa, HTB-5, and J82 cell lines (Fig. 5, lane 14) .
Discussion
The GWAS association between SNP rs2294008 within the PSCA gene and bladder cancer susceptibility was originally reported by Wu et al. (15) and has been subsequently confirmed by Rothman et al. (14) , in which rs2294008 had a per-allele OR = 1.13 (95% CI = 1.09-1.17, P = 4.4 × 10
) in the combined set of 10,196 cases and 44,705 controls. Here, we used imputation and selected genotyping followed by a conditional association analysis to fine-map this region. We confirmed that rs2294008 captured the main association with bladder cancer susceptibility in the PSCA region. Based on fine-mapping, we provide evidence for a unique signal detected by rs2978974, located 10 Kb upstream of rs2294008. We found that there was statistically significant interaction between the two SNPs, with an increased bladder cancer risk among carriers of risk alleles from both SNPs. This finding does, however, require replication in future studies. Higher PSCA mRNA expression was detected in bladder tumor samples compared with adjacent normal bladder tissue, with enhanced expression specifically present among carriers of the risk allele T of rs2294008. Although no effect on mRNA expression was observed for rs2978974, we detected a strong and specific binding of nuclear proteins from five human cancer cell lines to the non-risk allele G. Absence of similar binding to the risk A allele of rs2978974 suggests the disruption of a regulatory function as a possible mechanism for this risk variant. Although it seems less likely that these two SNPs affect the same molecular mechanism, such as mRNA expression, they might be involved in two independent mechanisms that contribute to increased bladder cancer risk. Both rs2294008 and rs2978974 have differences in minor allele frequencies in distinct populations (Table S7) , reflected in population-specific LD patterns in this region (Fig. S1 ). All of the subjects in our GWAS were evaluated for differences in underlying population substructure using population-specific genetic markers, and samples with significant non-European admixture were excluded; additional follow-up samples were of self-described ethnicity. The observed heterogeneity (Fig. S6 ) might be the result of higher population admixture in some of the studies or because of chance alone.
Although the risk allele T of rs2294008 was associated with increased mRNA expression both in bladder tumor and adjacent normal tissue samples, this functional effect might be attributed to any of the 46 variants that were in high LD (r 2 > 0.8) with rs2294008 ( Fig. 1 and Dataset S1). The risk allele T of rs2294008 creates a novel translation start site nine amino acids upstream of the regular start site, extending PSCA leader peptide from 11 to 20 amino acids (Fig. S2) . The functional significance of this extension of the PSCA protein is currently under active evaluation.
In contrast with rs2294008, rs2978947 is a distinct variant not in strong LD with other markers (r 2 max = 0.19; Dataset S1). We located rs2978974 in an untranslated alternative first exon of the PSCA gene, 10 Kb upstream of rs2294008. This alternative exon is spliced directly to exon 2 of PSCA, generating a low-expressing mRNA transcript that is predicted to encode a protein unrelated to PSCA. In the published datasets (27, 28), the area surrounding rs2978974 contains strong epigenetic marks represented by methylation of histone 3 at lysine 4 (H3K4me2 and H3K4me3), which are often found to be associated with active regulatory elements such as promoters and enhancers (29). Because rs2978974 is a noncoding SNP located in an alternative untranslated first exon of the PSCA gene, it is reasonable to speculate that this SNP might function as a regulatory element for PSCA through allele-specific binding of transcription factors (30, 31).
We predicted that the non-risk G allele of rs2978974, but not the risk allele A, could bind ETS transcription factors, and ELK1, specifically. The 27 known ETS proteins modulate cell proliferation, differentiation, migration, invasiveness, and response to the microenvironment, which are the factors important for growth and metastasis of solid tumors (32, 33). ELK1 is specifically involved in the transcriptional regulation by forming a ternary complex with serum response factors at the c-fos serum response element (34), and has been shown as a regulator for vascular smooth muscle differentiation in the murine bladder (35). Our EMSA results with nuclear extracts from five cell lines confirmed the strong and allele-specific interaction with nuclear proteins, but the supershift assays with an anti-ELK1 antibody showed only a weak effect in the LNCaP prostate cancer cell line. It is possible that other ETS proteins are also involved in this regulation, and they are differentially expressed in prostate compared with bladder cancer cells. Recently, ELK1 expression was found elevated in an androgen-sensitive cell line LNCaP, but not in androgen-insensitive cell lines PC3 and DU-145 (36). We also observed that the allele-specific binding of rs2978974 was stronger in the DHT-treated cell line LNCaP compared with nontreated cells (Fig. 5) . There is an androgen receptor binding site located between rs2294008 and rs2978974 within the PSCA promoter region (Fig. 2) (37) , but the exact role of testosterone in regulation of PSCA function is still unclear.
In summary, using the results of a bladder cancer GWAS, we have identified SNP rs2978974 as an additional marker for bladder cancer susceptibility in the PSCA region of 8q24.3. The joint effect of risk alleles from the original GWAS signal rs2294008 and this recently identified marker rs2978974 suggests that both variants contribute to bladder cancer susceptibility. The risk allele A of rs2978974 might be related to the loss of binding to ELK1 or other ETS proteins, and the functional significance of rs2294008 or another variant in high LD with it could contribute to differential regulation of PSCA mRNA expression. 
Materials and Methods
Study subjects, genotyping, imputation, and association analyses are described in SI Materials and Methods. IMPUTE2 (38) was used to impute additional SNP genotypes based on the combined reference panel from the 1000 Genomes Project mRNA Expression Analysis. RNA-sequencing (RNA-seq) of bladder tissue samples was performed by the National Cancer Institute Core Sequencing Facility. PSCA mRNA expression was analyzed with the Human Gene ST1.0 expression array (Affymetrix) for the first set and with TaqMan expression assays for the second set of bladder tissue samples, as described in SI Materials and Methods.
DNA-Protein Interaction Analysis. Bioinformatic prediction analyses were performed with AliBaba2 (24) and TFSearch (25). Experimental testing of DNA-protein interactions for rs2978974 was performed with EMSA, as described in SI Materials and Methods. tionally, this research was supported by US Public Health Service Contracts N01-CN-45165, N01-RC-45035, and N01-RC-37004 from the National Cancer Institute, Department of Health and Human Services. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Additional funding information is provided in SI Materials and Methods. . For each SNP we evaluated the imputation performance using the average posterior probability for the bestguessed genotypes, and the IMPUTE2-info score, which is associated with the imputed allele frequency estimate ranging from 1 to 0 (high to low confidence). Markers with a posterior probability <0.9 or IMPUTE2-info score <0.9 were excluded from association analyses. Fisher's exact tests of the Hardy-Weinberg equilibrium (HWE) for controls were conducted for all SNPs. Linkage disequilibrium (LD) measures (D′ and r 2 ) were estimated using Haploview (6) . To account for imputation uncertainty, the estimated allelic dosage for each imputed marker was used in SNPTEST v2 (7) to test for association with bladder cancer risk. Similar association results were obtained using PLINK (8) with the best-guessed genotypes converted by GTOOL (9).
To test for the presence of independent signals in the PSCA region, we conditioned on the original GWAS marker rs2294008 in logistic regression models. We also examined joint effects by counting SNP genotypes and multiplicative SNP interactions by a log-likelihood ratio test. Additive SNP interaction was tested using RERI (relative excess risk due to interaction), AP (attributable proportion due to interaction), and S (synergy index), as suggested previously (10) . A recently developed likelihood ratio test without assuming the independence between the two SNPs was also used to test for interaction (11) . Stratified analyses and tests for multiplicative interaction were performed using a log-likelihood ratio test for the following factors: sex, smoking status, and tumor grade. All models were adjusted for age (in 5-y categories), sex, study sites and subregions, and smoking habit (current, former, or never) when applicable. Adjustment for study sites and subregions was used to control for population stratification, because it was found to best approximate eigenvalues of principle component analysis in the original GWAS (1). Meta-analysis, test for heterogeneity, and forest plots were performed with STATA version 11 (StatCorp). SequenceLDhot (12) was used to compute likelihood ratios for a set of putative recombination hotspots across the PSCA region, repeated with five nonoverlapping sets of 100 controls and using background recombination rates estimated by PHASE v2.1 (13) . All statistical tests were two-sided and conducted with SAS/STAT system version 9.2 (SAS Institute) unless otherwise stated. For the first set, DNA was isolated from tissue samples using Gentra Puregene DNA Isolation kit (Qiagen); DNA quantity and quality were determined by picogreen and microsatellite analysis before hybridization. Genotyping was performed on tumor DNA samples using the Illumina 1 M Duo array. RNA was prepared using GenElute Mammalian Total RNA Miniprep kit (Sigma) and RNA quantity and quality was determined by BioAnalyzer 2100 (Agilent). For the second set, DNA and RNA were extracted after tissue homogenization with Tissue Lyser (Qiagen). DNA was prepared with Gentra kit (Qiagen), and total RNA was prepared with mirVana kit (Ambion). DNA and RNA were quantified with Nanodrop (Thermo Scientific) and RNA integrity was certified with BioAnalyzer 2100 (Agilent). Genotyping was performed on normal and tumor tissue DNA, using predesigned Taqman genotyping assays for both SNPs (C__3288106_1 for rs2294008 and C__26732964_10 for rs2978974; Applied Biosystems). There was full concordance between genotypes for the tested markers in normal and tumor samples of 27 paired tissue samples.
RNA-Sequencing of Bladder-Tissue Samples. RNA-sequencing (RNAseq) of seven tumor and seven adjacent normal-bladder tissue samples from the second set was performed by the National Cancer Institute Core Sequencing Facility. Briefly, 1 μg of each total RNA sample was used for polyA mRNA selection and fragmentation, followed by ligation to 65-bp paired-end adaptors. Each library was enriched by 12 cycles of PCR and ran at a concentration of 4.5 pM on HiSeq2000 Sequencing Systems (Illumina) using one lane per sample. An average of 52 million of paired 107-bp reads were generated for each sample. All sequencing reads were processed and aligned to the UCSC Homo sapiens reference genome (hg19)
Cufflinks v.0.9.3 (16) was used to process the aligned reads to reconstruct transcripts based on Ensembl transcripts Homo_ sapiens.GRCh37.61 annotation (17) and identify novel and alternatively spliced transcripts. Fragments per kilobase of exon per million fragments mapped (FPKM) was used to measure the relative abundance of transcripts. Mapping results were visualized both with UCSC genome browser (18) and Integrative Genomics Viewer (19) .
PSCA mRNA Expression and cDNA Sequencing. For the first set of bladder-tissue samples, expression analysis was performed with the Human Gene ST1.0 expression array (Affymetrix). For the second set of samples, cDNA was synthesized using SuperScript III kit (Invitrogen) from 1 μg of total RNA using random hexamers. Expression of PSCA was measured with custom-designed TaqMan expression assays from Applied Biosystems using the following primers and probes: PSCA1a2-F: 5′-ACCCAATTTA-GATGATTCAGACGAT-3′; PSCA1a2-R: 5′-CAGCAGGGCA-GTGCTTAAGTC-3′; PSCA1a2_FAM-probe: 5′-TTTGAAA-CTTTTGAACTGGG-3′; PSCA123-F: 5′-CTGTGCTGCTTGC-CCTGTT-3′, PSCA123-R: 5′-GTTCAAGCTGCAGCCTTTGC-3′; PSCA123_FAM-probe: 5′-GCATCCGCGCAGTT-3′. Two endogenous controls, β2-microglobulin (B2M, assay Hs_00187842_m1) and GAPDH (assay 4352934) were used for normalization. Negative controls for the assays included 10 ng of genomic DNA and nuclease-free water. The reactions included cDNA generated from 10 ng of total RNA, 0.25 μL of 20× TaqMan gene expression assays, 2.5 μL of 2× Gene Expression Master Mix (Applied Biosystems). All reactions were performed in four technical replicates on the ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). Full-length PSCA cDNA from normal tissue of 45 bladder cancer patients was amplified using following primers: PSCA_Ex_1_F: 5′-GCTGCTTGCCCTGTTGAT-3′; PSCA_Ex2_F: 5′-CTGCTGTGCTACTCCTGCAA-3′; PSCA_Ex2_R: 5′-TTGC-AGGAGTAGCACAGCAG-3′; PSCA_Ex3_R: 5′-CTGTGAGT-CATCCACGCAGT-3′; and sequenced using a 3730xl DNA Analyzer (Applied Biosystems). SNP scoring was performed with Sequencher 4.8 software (GeneCodes).
Statistical Analysis of mRNA Expression. For the first set of bladder tumor samples, expression values were used for analysis after normalization with the Robust Multiarray Averaging method (20) . For the second set of samples, PSCA mRNA expression was normalized by the geometric mean of expression of two endogenous controls, B2M and GAPDH, according to the relative quantification method (21) . The expression values did not significantly deviate from normal distribution and were analyzed with parametric statistical tests. In both sets of samples, generalized linear models were used to test for the association between PSCA mRNA expression and SNP genotypes, with adjustment for the effect of age and sex. Joint effects and SNP interactions were also tested by combining 2-SNP genotypes and log-likelihood ratio test, respectively. A Student t test was used to compare the overall mRNA expression between bladder tumors and normal bladder tissue samples. All statistical tests were two-sided and conducted with SAS/STAT system version 9.2 (SAS Institute).
DNA-Protein Interaction Analysis. Bioinformatic prediction analyses of DNA-protein interactions were performed with AliBaba2 (22) and TFSearch (23) . Experimental testing of DNA-protein interactions for rs2978974 was performed with EMSA with following primers: rs2978974_A-F, 5′-GCTGCCTTCCAGTCACC-AGGA-3′; rs2978974_A-R, 5′-TCCTGGTGACTGGAAGGCA-GC-3′; rs2978974_G-F, 5′-GCTGCCTTCCGGTCACCAGGA-3′; rs2978974_G-R: 5′-TCCTGGTGACCGGAAGGCAGC-3′. Primers were labeled using a biotin 3′-end DNA labeling kit (Thermo Scientific), and the comparable efficiency of labeling was tested by dot-blots. Corresponding forward and reverse primers were annealed to create 3′-end biotin-labeled double-stranded probes. For each EMSA reaction, allele-specific labeled probes were incubated with ∼8 μg of commercial nuclear extracts from HeLa cervical cancer cell line (Active Motif; #36010), LNCaP prostate cancer cell line (Active Motif; #36051), and LNCaP treated with dihydrotestosterone (DHT), a more potent form of testosterone (Active Motif; #36067). For bladder cancer cell lines HTB-5 and J82, nuclear extracts were prepared using NE-PER Nuclear and Cytoplasmic Extraction Reagents (Thermo Scientific). The protein complexes were resolved on 6% DNA retardation gels (Invitrogen) for 1 h at 100 V, transferred to Biodyne B Nylon Membranes, cross-linked, and processed with the Chemiluminescent Nucleic Acid Detection Module (Thermo Scientific). A 50-and 200-fold excess of unlabeled probes was used for competition assays. For supershift assays, an anti-ELK1 antibody (sc-355 X; Santa Cruz) were preincubated with the nuclear extracts for 15 min at room temperature before addition of DNA probes. 
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P-interaction between grade and rs2294008 ‡ = 0.7145 *Estimates from logistic regression models assuming log-additive genetic effect, adjusted for study sites/regions, age, sex, and smoking status when applicable. † Estimates from logistic regression models assuming log-additive genetic effect, adjusted for study sites/regions, age, sex, and smoking status when applicable. ‡ Estimates from log-likelihood ratio test for multiplicative SNP interaction, adjusted for study sites/regions, age, sex, and smoking status when applicable. Table S4 . Association between PSCA SNP rs2978974 and bladder cancer risk stratified by study sites, sex, smoking status, and tumor grades 
